anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. ^ SUBSTANCE: claimed invention relates to field of medicine, namely to dentistry, and can be used in treatment of patients with chronic generalised periodontitis. Method includes removal of over- and under- gum dental plaques, application in area of upper and lower jaws of periodontal dressing with gel, containing active substance in amount 5% and base, including polyethylene glycol 400. Dressings are applied until inflammation in periodontium tissues is relieved, applying gel, which contains as 5% active substance dibunol and additionally as active substance chlorhexidine gluconate in form of 20% solution, and as base, it additionally contains glycerol, Vaseline oil, cremophor RH-40, aerosil and purified water. ^ EFFECT: application of invention makes it possible to create high medication concentration for short term with further effect of medicinal action prolongation, including etiotropic, antioxidant and immunocorrecting action. ^ 2 cl, 3 ex
The invention relates to a Chinese and western medicine compound medicinal preparation for treating gout. The Chinese and western medicine compound medicinal preparation is prepared from traditional Chinese medicine ingredients and Western medicine ingredients, wherein the main traditional Chinese medicine ingredients are as follows: zaocys dhumnade, potentilla multifida, scorzonera divaricata, monkshood, kohlrabi, caulis spatholobi, asarum, caulis sinomenii, geranium wilfordii, notopterygium root, seeds of Glycine max (L.) Merr., leech, orchis, radix clematidis, polytichum commune hedw, rhizoma panacis majoris, rhizome of himalayan xylanche, garden balsam stem, melinis repens, centipeda minima, Thesium chinense Turcz., Polycarpaea corymbosa (L.) Lam., veratrum taliense, Myriactis nepalensis Less., twin-sorus fern, Vaccinium fragile Franch. var. mekongense (W. W. Sm.) Sleum., yam rhizome and herb of white chinaure; and the Western medicine ingredients are as follows: prednisone acetate, chondroitin sulfate, vitamin K, chlorpheniramine maleate, dextranum, sodium humate, docosahexaenoic acid, casein phosphopeptides and sorbitol. The medicinal preparation is obvious in effect and low in cost.
FIELD: medicine, phthisiology. SUBSTANCE: method can be used in treatment of caseous pneumonia. On the background of carrying out anti-tuberculosis chemotherapy method involves prescription of the following drugs as daily dosing: isoniazid, 5 mg per 1 kg of body mass (mg/kg) of patient, rifampicin, 10 mg/kg, pyrazinamide, 25 mg/kg, and streptomycin, 15 mg/kg and abisib additionally, by 1 table spoon, 3 times per a day, 30 min before eating and its phytoncide fraction, by 2 table spoons, before dinner being dissolved preliminary in 50 ml of water. Invention promotes to the enhanced effectiveness of treatment of patients with caseous pneumonia by means of elimination of intoxication symptoms, normalization of blood system indices, reducing adverse responses to anti-tuberculosis chemotherapy using the preparation of vegetable origin abisib and its phytoncide fraction. EFFECT: enhanced effectiveness of treatment, valuable medicinal properties of preparation. 6 tbl, 1 ex
BACKGROUND: Dysglycaemia increases the risk of myocardial infarction and subsequent recurrent cardiovascular events. However, the role of dysglycaemia in ischemia/reperfusion injury with development of irreversible myocardial tissue alterations remains poorly understood. In this study we aimed to investigate the association of ongoing dysglycaemia with persistence of infarct core iron and their longitudinal changes over time in patients undergoing primary percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI).
METHODS: We analyzed 348 STEMI patients treated with primary PCI between 2016 and 2021 that were included in the prospective MARINA-STEMI study (NCT04113356). Peripheral venous blood samples for glucose and glycated hemoglobin (HbA1c) measurements were drawn on admission and 4 months after STEMI. Cardiac magnetic resonance (CMR) imaging including T2 * mapping for infarct core iron assessment was performed at both time points. Associations of dysglycaemia with persistent infarct core iron and iron resolution at 4 months were calculated using multivariable regression analysis.
RESULTS: Intramyocardial hemorrhage was observed in 147 (42%) patients at baseline. Of these, 89 (61%) had persistent infarct core iron 4 months after infarction with increasing rates across HbA1c levels (<5.7%: 33%, ≥5.7: 79%). Persistent infarct core iron was independently associated with ongoing dysglycaemia defined by HbA1c at 4 months (OR: 7.87 [95% CI: 2.60-23.78]; p < 0.001), after adjustment for patient characteristics and CMR parameters. The independent association was present even after exclusion of patients with diabetes (pre- and newly diagnosed, n = 16).
CONCLUSIONS: In STEMI patients treated with primary PCI, ongoing dysglycaemia defined by HbA1c is independently associated with persistent infarct core iron and a lower likelihood of iron resolution. These findings suggest a potential association between ongoing dysglycaemia and persistent infarct core iron, which warrants further investigation for therapeutic implications.
Absorption

Etodolac extended-release tablets and etodolac tablets both contain etodolac, but differ in their release characteristics. The systemic availability of etodolac from etodolac extended-release tablets is generally greater than 80%. Etodolac does not undergo significant first-pass metabolism following oral administration. After oral administration of etodolac extended-release tablets in doses up to 800 mg once daily, peak concentrations occur approximately 6 hours after dosing and are dose proportional for both total and free etodolac.

Table 1 shows the comparison of etodolac pharmacokinetic parameters after the administration of etodolac tablets and etodolac extended-release tablets. 

Table 2 shows the etodolac pharmacokinetic parameters in various populations. The data from patients with renal and hepatic impairment were obtained following administration of (immediate-release) etodolac tablets.
Participants will be led through a beginner yoga course taught by a certified yoga instructor. Classes will meet three times a week for 60 minutes over the 6 month study duration. Sessions will focus on yoga postures, breathing, and meditative practices and may utilize mats, blocks, belts, and blankets.
PURPOSE:To provide a liquid cosmetic having a transparency higher than a specific level and exhibiting sufficiently high antiseptic mildew-proofing effect. CONSTITUTION:This liquid cosmetic is produced by compounding (A) one or more kinds of an N-(long-chain acyl) basic amino acid derivative of the formula I or the formula II (RCO is 6-20C saturated or unsaturated fatty acid residue; X is NH2, OCH3, OC2H5, OC3H7, OC4H9 or OCH2C6H5; (n) is 3 or 4), e.g. N- cocoyl-L-arginine ethyl ester PL-pyrrolidonecarboxylic acid salt with (B) 2- phenoxyethanol. The amount of the component A is 0.001-0.5wt.%, preferably 0.005-0.1wt.% and that of the component B is 0.1-1.0wt.%. The combination of both components is stable in the liquid cosmetic, free from undesirable effect on the safety of the cosmetic itself and resistant to the crystal deposition and clouding even by leaving standing at a low temperature. It exhibits strong inhibiting effect on general microorganisms and sufficient effect at a small amount compared with the separate use of the individual component.
Nucleotide-binding domain and leucine-rich repeat (NLR) proteins play crucial roles in immunity against pathogens in both animals and plants. In solanaceous plants, activation of several sensor NLRs triggers their helper NLRs, known as NLR-required for cell death (NRC), to form resistosome complexes to initiate immune responses. While the sensor NLRs and downstream NRC helpers display diverse genetic compatibility, molecular evolutionary events leading to the complex network architecture remained elusive. Here, we showed that solanaceous NRC3 variants underwent subfunctionalization after the divergence of Solanum and Nicotiana, altering the genetic architecture of the NRC network in Nicotiana. Natural solanaceous NRC3 variants form three allelic groups displaying distinct compatibilities with the sensor NLR Rpi-blb2. Ancestral sequence reconstruction and analyses of natural and chimeric variants identified six key amino acids involved in sensor-helper compatibility. These residues are positioned on multiple surfaces of the resting NRC3 homodimer, collectively contributing to their compatibility with Rpi-blb2. Upon activation, Rpi-blb2-compatible NRC3 variants form membrane-associated punctate and high molecular weight complexes, and confer resistance to the late blight pathogen Phytophthora infestans. Our findings revealed how mutations in NRC alleles lead to subfunctionalization, altering sensor-helper compatibility and contributing to the increased complexity of the NRC network.
The invention provides a traditional Chinese medicine acupoint application for treating phlegm-dampness lung-accumulation type cough, and belongs to the technical field of traditional Chinese medicine application. Comprises the following components in parts by mass: 12-16 parts of scutellaria baicalensis, 12-16 parts of semen lepidii, 12-16 parts of rheum officinale, 9-12 parts of ephedra, 9-12 parts of lumbricus, 6-10 parts of asarum, 6-10 parts of rhizoma pinellinae praeparata, 6-10 parts of pericarpium citri reticulatae and 6-10 parts of rhizoma zingiberis. The preparation method of the Chinese medicinal acupoint application comprises mixing the above materials, pulverizing into powder, sieving, adding Mel and green tea water, making into paste, pressing into medicinal cake, and applying on sterile dressing plaster. The traditional Chinese medicine acupuncture point is applied to the acupuncture point of a patient and kept for 4-6 h/day once a day, and can be used for treating phlegm-dampness lung-accumulating type cough. The Chinese medicine acupoint application has simple manufacturing and using methods and is easy to be accepted by patients; the points can be flexibly selected, and the individual treatment of the traditional Chinese medicine is reflected, because of the essence of treatment of people. The Chinese medicine acupoint application disclosed by the invention has the effects of promoting qi circulation, eliminating dampness, warming lung, eliminating phlegm and relieving cough, and is used for treating phlegm-damp accumulation in lung type cough, and the effect is obvious after the acupoint application for 3-7 days.
The invention discloses a traditional Chinese medicine composition for treating climacteric syndrome. The traditional Chinese medicine composition is prepared from the following crude drugs: radix bupleuri, radix paeoniae alba, radix curcumae, dogwood, common yam rhizome, mulberry fruit, spina date seed, light wheat, tuber fleeceflower stem, keel, oyster, lotus nut, lily, prepared rehmannia root, rhizoma anemarrhenae, astragalus membranaceus, radix ophiopogonis, schisandra chinensis, fruit of Chinese wolfberry, seed of Chinese dodder, tuckahoe, bighead atractylodes rhizome, root bark of the peony tree, corbicula, soybean sprout, tortoise shell, laportea, bayuezha (Chinese character), filbert, and nacre mother of pearl. The traditional Chinese medicine composition can treat the climacteric syndrome, and can soothe the liver and regulate qi, nourish yin and invigorate the spleen, and nourish yin and yang. The technology has the advantages of being convenient to dose, through in affected part, strong in targeting property, low in cost and the like; and a drug is easily prepared. The traditional Chinese medicine composition adopts different drug properties of traditional Chinese medicinal materials; scientific formulation is carried out; and an ideal treatment effect can be achieved. The traditional Chinese medicine composition is safe, and free of toxic and side effects, can replenish the vital essence and remove heat in combination of oral administration and external application, and can eliminate dampness and dredge channels, and remove pain.
Patients will be screened daily. Patients who meet eligibility criteria will be approached for participation. Patients interested in participating will proceed through informed consent. Once informed consent is obtained, an initial questionnaire will be administered, a blood draw will be performed to assess for baseline Vitamin D/O3FA concentration and immune profile. Then patients will be randomized into one of 4 treatment arms in 1:1:1:1 allocation. Patients will receive study drug for 6 weeks following burn injury. Adverse event monitoring will occur daily while inpatient and weekly once discharged from the hospital through 6 weeks. Patient compliance with the study drug will be assessed via patient-reported reported missing doses, pill counts at the end of the study, and a 6-week blood draw in which Vitamin D/O3FA levels and immune profile will be assessed. Patient-reported outcomes will be collected via follow-up survey at 6 weeks, 3 months, 6 months, and 1 year following burn injury.s, and 1 year following burn injury.
Multiple sclerosis (MS) is a chronic immune-mediated disease involving inflammation, plaques, and demyelination in the central nervous system . MS typically affects people in early adulthood in the 20-40 year range and is two to three times more common in women than men. Exercise therapy is one of the greatest and most well-researched rehabilitation strategies for multiple sclerosis patients. Exercise therapy includes a variety of exercise methods, including resistance training and endurance training, all of which are suitable for multiple sclerosis patients to use. Exercise can alter a wide range of functional and health-related factors as well as the diversity of symptoms displayed by multiple sclerosis patients.Pilates is a method of physical exercise that focuses on core stability, strength, flexibility, posture, muscle control, breathing, and mind-body connection.Yoga therapy is the process of empowering individuals to progress toward improved health and well-being through the application of the philosophy and practice of Yoga. Practicing yoga can provide the tools to help patients with multiple sclerosis cope with the disease and manage everyday tasks in a more beneficial way .Tai Chi is a martial art of Chinese origin that is based on the development of inner energy by practicing predetermined movements softly. It is an intense and complete practice, beneficial at any age. Tai Chi thus falls within a long tradition in Chinese therapies and exercises to improve the individuals' quality of life. 100 patients with multiple sclerosis will be allocated randomly to four groups; group1 will receive pilates plus traditional therapy, group 2 will receive yoga plus traditional therapy, group 3 will receive tai chi plus traditional therapy and group 4 will receive traditional therapy only.
Pulmonary arterial hypertension (PAH) is an obstructive vasculopathy that, if not promptly treated, culminates in right heart failure. Therefore, pre-clinical studies are needed to support and optimize therapeutic approaches of PAH. Here, we explore a prospective function of sevoflurane in experimental PAH through regulating TRAF6. Monocrotaline (MCT)-induced PAH rats were subjected to sevoflurane inhalation and intratracheal instillation of lentivirus overexpressing TRAF6. Platelet-derived growth factor (PDGF)-treated pulmonary artery smooth muscle cells (PASMCs) were exposed to sevoflurane and genetically manipulated for TRAF6 overexpression. It was found that MCT and PDGF challenge upregulated the levels of TRAF6 in rat lung tissues and PASMCs, but sevoflurane treatment led to reduced TRAF6 expression. Sevoflurane inhalation in MCT-induced rats resulted in alleviative pulmonary vascular remodeling, mitigated right ventricular dysfunction and hypertrophy, improved mitochondrial function and dynamics, and inactivation of NF-κB pathway. In vitro studies confirmed that exposure to sevoflurane repressed PDGF-induced proliferation, migration, and phenotype switching of PASMCs, and suppressed mitochondrial dysfunction and NF-κB activation in PDGF-stimulated PASMCs. The beneficial impact of sevoflurane on pathological changes of lung and cell phenotype of PASMCs were reversed by overexpression of TRAF6. In summary, our study suggested the protective properties of sevoflurane in targeting PAH by downregulating TRAF6 expression, providing a novel avenue for the management of PAH.
Epigenetic changes have long-lasting impacts, which influence the epigenome and are maintained during cell division. Thus, human genome changes have required a very long timescale to become a major contributor to the current obesity pandemic. Whereas bidirectional effects of coronavirus disease 2019 (COVID-19) and obesity pandemics have given the opportunity to explore, how the viral microribonucleic acids (miRNAs) use the human's transcriptional machinery that regulate gene expression at a posttranscriptional level. Obesity and its related comorbidity, type 2 diabetes (T2D), and new-onset diabetes due to severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) are additional risk factors, which increase the severity of COVID-19 and its related mortality. The higher mortality rate of these patients is dependent on severe cytokine storm, which is the sum of the additional cytokine production by concomitant comorbidities and own cytokine synthesis of COVID-19. Patients with obesity facilitate the SARS-CoV-2 entry to host cell via increasing the host's cell receptor expression and modifying the host cell proteases. After entering the host cells, the SARS-CoV-2 genome directly functions as a messenger ribonucleic acid (mRNA) and encodes a set of nonstructural proteins via processing by the own proteases, main protease (Mpro), and papain-like protease (PLpro) to initiate viral genome replication and transcription. Following viral invasion, SARS-CoV-2 infection reduces insulin secretion via either inducing β-cell apoptosis or reducing intensity of angiotensin-converting enzyme 2 (ACE2) receptors and leads to new-onset diabetes. Since both T2D and severity of COVID-19 are associated with the increased serum levels of pro-inflammatory cytokines, high glucose levels in T2D aggravate SARS-CoV-2 infection. Elevated neopterin (NPT) value due to persistent interferon gamma (IFN-γ)-mediated monocyte-macrophage activation is an indicator of hyperactivated pro-inflammatory phenotype M1 macrophages. Thus, NPT could be a reliable biomarker for the simultaneously occurring COVID-19-, obesity- and T2D-induced cytokine storm. While host miRNAs attack viral RNAs, viral miRNAs target host transcripts. Eventually, the expression rate and type of miRNAs also are different in COVID-19 patients with different viral loads. It is concluded that specific miRNA signatures in macrophage activation phase may provide an opportunity to become aware of the severity of COVID-19 in patients with obesity and obesity-related T2D.
By coating the surface of a powder comprising a silicone resin and/or an organic powder with a specific hydrophilizing agent, such powder is hydrophilized. The hydrophilizing agent includes water-soluble polyoxyalkylene glycol derivatives. The organic powder is at least one selected from PMMA, nylon, polyester, polystyrene, cellulose, silicone elastomer powder, silicone rubber powder, benzoguanamine, styrenedivinylbenzene pinhole polymer, ethylene tetrafluoride, polyethylene powder, polypropylene powder, polyurethane powder, silk powder, metal soap powder, starch powder, N-acylated lysine, an organic pigment, and a composite of at least one of these organic powders described above with a metal oxide and/or a metal hydroxide. Such coated (treated) powder has extremely great dispersibility (ease of dispersion) and very good dispersion stability (long-term dispersion stability with lapse of time) in aqueous dispersion media, particularly under acidic and alkaline conditions, specifically at pH 3 through 13. Using the surface-treated powder, additionally, a dispersion with good dispersibility (ease of dispersion) and great dispersion stability, preferably for cosmetics can be provided. The use of the surface-treated powder, or the use of the dispersion can provide further a cosmetic excellent in dispersibility and dispersion stability and further in re-dispersibility and dispersion stability with lapse of time and smooth feeling as compared to the related art when selecting aqueous cosmetic as an agent form.
PURPOSE: A colonic purgative composition containing polyethylene glycol and vitamin C and a pharmaceutical formulation containing the same are provided to enhance storage stability and to be used for colonic irrigation before surgery. CONSTITUTION: A colonic purgative composition contains 100 parts by weight of a first pharmaceutical ingredient, polyethylene glycol, 5-15 parts by weight of a second pharmaceutical ingredient, vitamin C, and 0.01-3 parts by weight of a third pharmaceutical ingredient, sweetener. The first or third pharmaceutical ingredient is manufactured in the form of a coated granule, a coated tablet, or capsule. The third pharmaceutical ingredient is manufactured in the form of a coated granule, a coated tablet, capsule, or tablet. The composition additionally contains 0.01-3 parts by weight of flavoring agent. [Reference numerals] (AA) Left: powder before coating; (BB) Right: power after coating(PVA/PMMA 5%, fluid-bed granulator is used); (CC) Embodiment 46(6 month later); (DD) Comparative embodiment 02(6 month later); (EE) Determination: none; (FF) Determination: serious change
Participants will receive E7386, tablets, orally, twice daily in 28-days treatment cycle until PD, development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. The dose of Expansion Part 2 will be based on the available safety data from Dose Escalation and Expansion Part 1 of the study.
A method of treating neurodegenerative diseases using hUCB plasma is presented herein. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3/7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity suggest that the use of hUCB plasma alone, or with stem cells, may prove useful as a therapeutic in ALS patients. hUCB plasma was shown to increase therapeutic efficacy of MNCs as well as decrease apoptosis of MNCs. The cytokine profile of hUCB plasma supports its usefulness as a sole therapeutic as well as an additive to MNCs.
The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds provided by the invention; methods of treating of various diseases, disorders, and conditions by using the compounds provided by the invention; processes for preparing the compounds provided by the invention; intermediates for the preparation of the compounds provided by the invention; solid forms of the compounds provided by the invention; and methods of using the compounds in in-vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds provided by the invention have a formula I-l. The formula I-1 is shown in the description, wherein the variables are as defined herein. Additionally, the compounds provided by the invention have a formula II, or a pharmaceutically acceptable salt thereof. The formula I-2 is shown in the description wherein the variables are as defined herein.